Patents by Inventor Jack HEATH

Jack HEATH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20260035693
    Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.
    Type: Application
    Filed: September 23, 2024
    Publication date: February 5, 2026
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Jennifer Leah GORI, Edouard AUPEPIN DE LAMOTHE-DREUZY, Jack HEATH, John Anthony ZURIS, KaiHsin CHANG
  • SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20250250588
    Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci in cells and increasing expression of fetal hemoglobin.
    Type: Application
    Filed: June 18, 2024
    Publication date: August 7, 2025
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Edouard AUPEPIN DE LAMOTHE-DREUZY, KaiHsin CHANG, Minerva Elaine SANCHEZ, Jack HEATH
  • GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC GRANULOMATOUS DISEASE
    Publication number: 20250243474
    Abstract: Provided herein are compositions and methods of using prime editing systems comprising prime editors and prime editing guide RNAs for treatment of genetic disorders.
    Type: Application
    Filed: October 1, 2024
    Publication date: July 31, 2025
    Inventors: Jennifer L. Gori, David Waterman, Jack Heath, Andrew V. Anzalone
  • SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20250179488
    Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.
    Type: Application
    Filed: July 3, 2024
    Publication date: June 5, 2025
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Jennifer Leah GORI, Edouard AUPEPIN DE LAMOTHE-DREUZY, Jack HEATH, John Anthony ZURIS, KaiHsin CHANG
  • SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20240417706
    Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.
    Type: Application
    Filed: December 22, 2023
    Publication date: December 19, 2024
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Jennifer Leah GORI, Luis A. BARRERA, Edouard AUPEPIN DE LAMOTHE-DREUZY, Jack HEATH
  • Systems and methods for the treatment of hemoglobinopathies
    Patent number: 12031132
    Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: July 9, 2024
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Jennifer Leah Gori, Edouard Aupepin De Lamothe-Dreuzy, Jack Heath, John Anthony Zuris, KaiHsin Chang
  • MODIFIED CELLS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20240191197
    Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci in cells and increasing expression of fetal hemoglobin.
    Type: Application
    Filed: December 9, 2020
    Publication date: June 13, 2024
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Jennifer Leah GORI, Edouard AUPEPIN DE LAMOTHE-DREUZY, Jack HEATH, John Anthony ZURIS, KaiHsin CHANG
  • CRISPR/RNA-guided nuclease systems and methods
    Patent number: 11963982
    Abstract: Genome editing systems, guide RNAs, dead guide RNAs, and CRISPR-mediated methods are provided for altering portions of a target nucleic acid.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: April 23, 2024
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Edouard Aupepin De Lamothe-Dreuzy, Jack Heath, Jennifer Leah Gori, Luis Barrera
  • GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC GRANULOMATOUS DISEASE
    Publication number: 20240011007
    Abstract: Provided herein are compositions and methods of using prime editing systems comprising prime editors and prime editing guide RNAs for treatment of genetic disorders.
    Type: Application
    Filed: August 14, 2023
    Publication date: January 11, 2024
    Inventors: Jennifer Gori, David Waterman, Jack Heath, Andrew V. Anzalone
  • Systems and methods for the treatment of hemoglobinopathies
    Patent number: 11851690
    Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: December 26, 2023
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Jennifer Leah Gori, Luis A. Barrera, Edouard Aupepin De Lamothe-Dreuzy, Jack Heath
  • SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20220073951
    Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci in cells and increasing expression of fetal hemoglobin.
    Type: Application
    Filed: September 11, 2020
    Publication date: March 10, 2022
    Inventors: Jennifer Leah GORI, Edouard AUPEPIN DE LAMOTHE-DREUZY, Jack HEATH
  • SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20220047637
    Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.
    Type: Application
    Filed: November 27, 2019
    Publication date: February 17, 2022
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Edouard AUPEPIN DE LAMOTHE-DREUZY, KaiHsin CHANG, Jack HEATH
  • SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20220025363
    Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.
    Type: Application
    Filed: December 8, 2020
    Publication date: January 27, 2022
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Jennifier Leah GORI, Edouard AUPEPIN DE LAMOTHE-DREUZY, Jack HEATH, John Anthony ZURIS, KaiHsin CHANG
  • SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20210254061
    Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.
    Type: Application
    Filed: September 11, 2020
    Publication date: August 19, 2021
    Inventors: Jennifer Leah GORI, Edouard AUPEPIN DE LAMOTHE-DREUZY, Jack HEATH, John Anthony ZURIS, KaiHsin CHANG
  • SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20210230638
    Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci in cells and increasing expression of fetal hemoglobin.
    Type: Application
    Filed: September 4, 2020
    Publication date: July 29, 2021
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Edouard AUPEPIN DE LAMOTHE-DREUZY, KaiHsin CHANG, Minerva Elaine SANCHEZ, Jack HEATH
  • SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20200157515
    Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.
    Type: Application
    Filed: September 12, 2019
    Publication date: May 21, 2020
    Inventors: Jennifer Leah GORI, Luis A. Barrera, Edouard Aupepin De Lamothe-Dreuzy, Jack Heath
  • CRISPR/RNA-GUIDED NUCLEASE SYSTEMS AND METHODS
    Publication number: 20200155606
    Abstract: Genome editing systems, guide RNAs, dead guide RNAs, and CRISPR-mediated methods are provided for altering portions of a target nucleic acid.
    Type: Application
    Filed: November 8, 2019
    Publication date: May 21, 2020
    Applicant: Editas Medicine, Inc.
    Inventors: Edouard AUPEPIN DE LAMOTHE-DREUZY, Jack HEATH, Jennifer LEAH GORI, Luis BARRERA